Eli Lilly's Point Biopharma acquisition doesn't change our optimism on the diabetes-and-obesity drug giant heading into the new year.
Comments
( ゚Д゚)
There's nothing here…
Eli Lilly's Point Biopharma acquisition doesn't change our optimism on the diabetes-and-obesity drug giant heading into the new year.